Quanterix Corporation Marketable Securities, Unrealized Gain (Loss)
Quanterix Corporation (QTRX) reported Marketable Securities, Unrealized Gain (Loss) of $241.00 thousand for the 9-month period ending 2023-09-30, per its 10-K/A filed 2024-12-26.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2024-12-26
- 2023-09-30: Marketable Securities, Unrealized Gain (Loss) 9 month $241.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 9 month |
|---|---|
| 2023-09-30 | $241.00K 10-K/A · filed 2024-12-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |